Table 1 Characteristics of the sample and its cohorts.
From: On the utility of cerebrospinal fluid biomarkers in canine neurological disorders
MUO (n = 47) | CM/SM/M (n = 29) | Tumors (n = 19) | Epileptic control (n = 66) | |
|---|---|---|---|---|
Sex—f/m | 25/22 | 13/16 | 8/11 | 26/40 |
Age—median (range) | 8.0 (1.0, 15.5) | 5.0 (0.5, 12.0) | 11.5 (6.5, 12.5) | 6.5 (0.5, 16.0) |
Aβ1-42 (pg/mL) (Fig. 1A) | ||||
n | 45 | 27 | 19 | 65 |
Mean, SD | 1597.35 (564.93) | 1820.93 (450.04) | 1256.29 (305.80) | 1833.79 (435.71) |
95% CI | 1427.62, 1767.07 | 1642,90 1998.96 | 1108.90, 1403.69 | 1725.82, 1941.75 |
NfL (pg/mL) Fig. 1B | ||||
n | 30 | 20 | 18 | 48 |
Mean, SD | 21,556.00 (25,169.66) | 11,247.10 (15,914.85) | 5982.15 (3862.96) | 1201.02 (994.89) |
95% CI | 12,157.50, 30,954.51 | 3798.72, 18,695.48 | 4061.15, 7903.16 | 912.14, 1489.91 |
NSE (pg/mL) Fig. 1C | ||||
n | 30 | 21 | 18 | 48 |
Mean, SD | 47.83 (42.84) | 46.44 (40.79) | 83.23 (48.59) | 31.15 (31.33) |
95% CI | 31.84, 63.83 | 27.87, 65.00 | 59.07, 107.39 | 22.05, 40.25 |
Total tau (pg/mL) (Fig. 1D) | ||||
n | 45 | 29 | 19 | 65 |
Mean, SD | 82.92 (67.19) | 48.65 (29.68) | 68.60 (36.63) | 31.45 (10.43) |
95% CI | 62.73, 103.10 | 37.36, 59.94 | 50.94, 86.25 | 28.87, 34.04 |
